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Myocarditis is an infectious–inﬂammatory disease often superimposed to individual
genetic background which could favour or inhibit its progression into a chronic heart
muscle disorder (most often dilated cardiomyopathy, rarely arrhythmogenic, or
right-sided cardiomyopathy). Post-myocarditis cardiomyopathy is likely caused by a
complex interaction between the viral infection and an individual predisposition.
Some viruses are able to highlight a clinical phenotype replicating a model similar to
the genetically determined conditions, while other can affect the resolution or the
progressive remodelling of the left ventricle after the infectious process. The identi-
ﬁcation of speciﬁc individual genetic backgrounds, or genes favouring the progres-
sion of the disease, are important future research goals for precision medicine aim-
ing at a speciﬁc and individualized treatment for patients affected with myocarditis.
Introduction
Since 25 April 1953, when James Watson and Francis Crick
delineated the structure of Deoxyribonucleic Acid (DNA),
researchers have outlined multiple and complex systems
regulating the interaction between genes and proteins.
The axiom ‘one gene-one protein’ has been progressively
modified till becoming ‘one sequence-multiple effects’.
DNA, in fact, does not only include protein producing
information but is loaded with other fundamental compo-
nents [from the histone interactions to the non-coding
Ribonucleic Acid (RNA) sequences]. Accordingly the pheno-
typic expression of a disease stem from the interplay
among a complex network of multiple genes, bio-
molecular mechanisms, and their reaction to the offending
agent. Therefore, the advance of precision medicine is rep-
resenting also a clinical challenge.
The goal of precision medicine implies the interaction
between the environmental factors and the genetic make-
up of the individual patient as to optimize their outcomes.
Myocarditis is an infectious–inflammatory disease often
superimposed to individual genetic background which
could favour or inhibit its progression into a chronic heart
muscle disorder (most often dilated cardiomyopathy
(DCM), rarely arrhythmogenic, or right-sided cardiomyopa-
thy). The complex interactions between these two compo-
nents are summarized in Table 1.
Dilated cardiomyopathy: the importance of
aetiology
Dilated cardiomyopathy is a myocardial condition charac-
terized by dilatation and systolic dysfunction of the left
ventricle, not caused by an identifiable pathological pro-
cess such as ischaemia, valvular disease, or hypertension.1
Considering the wide pathogenic variability, aetiological
characterization is a mainstay of clinical management of
DCM. There are several potentially reversible causes of left
ventricular dysfunction, such as myocarditis, but also
tachycardia induced myopathy, or related to catechol-
amine or toxic substances (alcohol/cocaine), all of which
are non-genetic/non-familial, and amenable to complete
resolution, as the offending agent is removed, particularly
if done in timely fashion. The new techniques of genetic se-
quencing, such as the next generation sequencing, ex-
panded our knowledge, during the last few years, of the
genetic causes of left ventricular dysfunction. Presently a
genetic origin is recognized in up to 50% of the patients
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with DCM.2 To date over 50 genes have been identified,
encoding for proteins responsible for several cellular struc-
tures, probably involved in common pathogenic pathways
(Table 2).3–6 Albeit the number has been progressively de-
creasing, there still remain a significant number of idio-
pathic DCM, representing almost 20% of non-ischaemic left
ventricular dysfunctions. This number embodies our inabil-
ity to provide a complete aetiological characterization of
the condition, although the vast majority of the cases are
likely connected to not yet identified genetic mutations, or
predominantly chronic inflammatory processes. In this con-
test myocarditis, with its possible evolution towards DCM,
constitute the area of most complex interaction among
genetic-immune-environmental causes.
Myocarditis as a cause of dilated
cardiomyopathy
Myocarditis constitutes a specific subgroup of myocardial
diseases, sometimes involving the pericardium, with in-
flammatory aetiology. The diagnosis of myocarditis is based
on histological, immunological, and immune-histochemical
criteria.7 Although the definition of myocarditis is well-
described, the disease is heterogeneous and, at times,
undetermined as far as pathophysiology, aetiology, clinical
presentation, and natural history.8 In fact potential causes
of myocarditis are infectious (bacteria, fungi, and protozo-
ans), as well as non-infectious agents (toxins, drugs, and
physical agents), and auto-immune conditions, hypersensi-
tivity, and hyper-catecholamines states.9 Nonetheless 95%
of myocarditis are secondary to a viral infection, and its
consequent immune response determining a pattern of
lymphocytic myocarditis (Table 3).9–11 The pathophysiolog-
ical mechanisms of lymphocytic myocarditis are the result
of the interaction between the offending agent and the
host immune response,12 and include three well-
recognized phases8:
(1) Acute phase (1–7 days). Direct infection with result-
ing cytolysis and apoptosis of the myocytes.
(2) Subacute phase (7 days–1 month). The immune re-
sponse is specific, and the myocardium is infiltrated
with T lymphocytes and macrophages which create
tissue damage despite a decrease in viral titration.
(3) Chronic phase (months–years). The immune re-
sponse attenuates and the condition evolves either
towards complete healing ‘restitutio ad integrum’
or post-inflammatory cardiomyopathy.
Myocarditis can occur without symptoms, or resemble a
myocardial infarction, or various stage of heart failure, or
with a wide range of ventricular and supraventricular
arrhythmias, and not infrequently manifest itself with sud-
den death. The natural history is highly variable spanning
from a complete uneventful resolution to the development
of post-inflammatory DCM.10 Some forms of myocarditis
manifest a favourable response to standard heart failure
treatment and immunosuppression and have a satisfactory
outcome, others, on the other hand, are characterized by
a persistent left ventricular dysfunction.10 The post-
myocarditis (or inflammatory) DCM is typified by a mid-
term (about 5 years) natural history similar to the classic
forms of genetic or idiopathic DCM.13 The early distinction
between the two behaviours ofmyocarditis is the challenge
for the future research. Furthermore would be important
to evaluate, in the long term, whether post-myocarditis
DCM maintains a progressive myocardial remodelling pro-
cess fuelled by a still active inflammatory process.13
Myocarditis and post-myocarditis dilated
cardiomyopathy: the role of genetics
There are four key moment in which the interaction
genetics-inflammatory process develops (Figure 1).
Myocarditis as a critical environmental factor in
the transition genotype/phenotype in dilated
cardiomyopathy
In post-myocarditis DCM, the origin of the condition is prob-
ably not homogenous.
There is, in fact, a complex interaction between genetic
and non-genetic causes, to the extent that DCM is the final
common pathway linking the offending agent and the indi-
vidual genetic make-up. Even though this general assertion
is widely acknowledged, the scientific evidences support-
ing it are scarce. Presently, for instance, the persistence of
viral genome inside the cardio-myocytes is debated, and
genetic variants and potentially pathogenic mutations
could favour the progression from myocarditis to DCM, or
on the other hand, portend to a favourable outcome.10
Genetic predisposition to infection/inflammation
Notwithstanding the high prevalence of infections in the
general population, is not completely clear why only a
small portion of them develops a myocarditis, and only a
portion of them will go on to DCM, emphasizing the role of
genetic predisposition in this setting. Our understanding of
this problem stemsmainly from animal models.
Animal models
Despite being infected with the same virus, only some
groups of mice, with definite genetic background, develop
myocarditis. The genetic predisposition is characterized by
Table 1 Key point in the interaction between offending
agent and genetic background for the predisposition to myo-
carditis and its possible evolution towards cardiomyopathy
1. Myocarditis is an infectious/inﬂammatory condition but in-
dividual genetic background plays an important role in the
predisposition to the infection/inﬂammation and in its pos-
sible evolution towards dilated cardiomyopathy.
2. Some viruses release speciﬁc proteases able to degrade or
integrate with proteins of cardiac myocytes thus reproduc-
ing condition similar to the genetically determined
disorders.
3. Some genotypes can affect either the resolution or, on the
other hand, the progressive left ventricular remodelling
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specific polymorphism both of themajor histocompatibility
complex, in particular human leucocyte antigen-DR4, and
of the proteins involved in the activation and intracellular
transduction of the signalling following infection.14 Knock-
out (KO) mice for genes codifying for proteins involved in
the anti-viral immune response [interferon-B, Toll-like re-
ceptor (TLR)-3], are more susceptible to both the
Coxsackievirus B3 (CVB3) myocarditis and its chronic pro-
gression.15 Furthermore the selective removal from the
cardiac myocytes of the receptor for Coxsackievirus and
Table 2 Genes most frequently implicated in genetic dilated cardiomyopathy
Gene Protein Percentage of cases with DCM Possible association/overlap
Autosomal dominant transmission
TTN 3 Titin 10–25 Limb girdle muscular dystrophy
Myopathy with cardiac and respiratory
muscular involvement
Tibial muscle dystrophy
LMNA Pre-lamin-A/C 6 Type 2 Charcot–Marie–Tooth neuropathy
Emery-Dreifuss muscular dystrophy
Hutchinson–Gilford Progeria
Werner syndrome
MYH7 Myosin-7 4.2 Laing myopathy
Hypertrophic cardiomyopathy
Non-compacted ventricle
MYH7 associated myopathy
MYH6 Myosin-6 3–4 Hypertrophic cardiomyopathy
SCN5A Sodium channel subunit a Type 5 2–4 Long QTsyndrome—Type 3
Brugada syndrome
Idiopathic ventricular ﬁbrillation
Sinus node disease
Conduction system disorders
MYBPC3 Myosin-binding protein 2–4 Hypertrophic cardiomyopathy
TNNT2 Troponin T 2.9 Hypertrophic cardiomyopathy
Non-compacted ventricle
Restrictive cardiomyopathy TTNT2 related
BAG3 Chaperon regulating protein 3 2.5 Progressive myoﬁbrillar myopathy
ANKRD1 Cardiac ankyrin 2.2
RBM20 RNA binding motif protein 1.9
TMPO Thymopoietin 1.1
LDB3 Proteina Enigma 3 1 Myoﬁbrillar myopathy
TCAP Telethonin 1 Hypertrophic cardiomyopathy
Limb girdle muscular dystrophy
VCL Vinculin 1
TPM1 Tropomyosin 1 <2 Hypertrophic cardiomyopathy
TNNI3 Troponin I 1.3 Hypertrophic cardiomyopathy
Restrictive cardiomyopathy
TNNC1 Troponin C <1.3 Hypertrophic cardiomyopathy
ACTC1 Actin <1 Hypertrophic cardiomyopathy
ACTN2 a-actin <1 Hypertrophic cardiomyopathy
DES Desmin <1 Desminopathy
Myoﬁbrillar myopathy
NEXN Nexilin <1 Hypertrophic cardiomyopathy
PSEN Presenilin-1 e2 <1 Alzheimer syndrome
SGCD Sarcoglycan delta <1 Limb girdle muscular dystrophy
PLN Phospholamban
DSG2 Desmoglein-2
X-linked transmission
DMD Dystrophin Duchenne and Becker muscular dystrophy
TAZ Tafazzin Barth syndrome
Type 2 endocardial ﬁbroelastosis
Non-compacted ventricle
Autosomal recessive transmission
TNNI3 Troponin I <1
Modiﬁed from Hershberger e Morales, Gene Review, 2015. Dilated Cardiomyopathy Overview.
B92 A. Cannata’ et al.
adenovirus, or KO mice for the receptor activated by
protease-2 (PAR2) seems to characterize phenotypes more
resistant to myocarditis despite an high viral load.16 Lastly
the complex interaction virus-cardiac myocytes-immune
system has a crucial role in the progression of the disease.
Evidences in humans
The evidences derived from human studies are less solid.
The role of genetic mutations pertaining to the innate
immunity in the susceptibility to myocarditis in humans has
been recently investigated.17 Alike the inferences from the
animalmodels, in human, inflammatory activation and ele-
vated levels of Interleukin (IL)-17, IL-1, tumour necrosis
factor (TNF)-a and dysregulation between metalloprotei-
nase and inhibitor of metalloproteinase, seems able to pre-
dict the progression towards DCM. Furthermore Casanova
group studied the role of immune system mutations in the
development of myocarditis by using cardiac myocytes de-
rived from induced Pluripotent Stem Cells (iPSCs) from hu-
man fibroblasts. Cardiac myocytes with mutation of the
genes codifying for proteins for the interferon-mediated
immune response [TLR-3 and Signal Transducer and
Activator of Transcription (STAT-1)], were not susceptible
to myocarditis. These results are somewhat restricted by
the fact that the study contemplates only the response of
cardiac myocytes to the infection, disregarding the impact
of the circulating factors, as well as the innate and the
cell-mediated immune response, crucial for the develop-
ment of myocarditis in vivo.17 Additionally this model is
based on cardiacmyocytes not completely mature, produc-
ing results which could be at variance from the mature
cells.18
The interference of some viruses with proteins
reproducing model similar to the genetically
determined forms
Enterovirus-produced specific proteases (2A and 3C, criti-
cal in the replication and successive cytolysis of cardiac
myocytes) could be responsible for a dilatative phenotype
in transgenic murine models, because of the selective ex-
pression, in the cardiac myocytes of these proteins.19 The
2A and 3C proteases are able to cleavage, among other pro-
teins, dystrophin and dysferlin, nuclear transcription fac-
tors and several caspase (cysteine-aspartic acid protease),
causing on one hand increased cytoplasmic membrane per-
meability, and on the other the dysregulation of the repar-
ative processes, and of the transmission of mechanical
force, as well as apoptosis and autophagia.16,20,21 More re-
cently, the role of microRNA (miRNA) has been highlighted
in the development of the infectious process. Patients with
myocarditis have an altered miRNA profile, even though
the specific dysregulation pattern has not yet been identi-
fied.19 All those mechanisms concur to the predisposition
tomyocarditis, as well as to its progression towards DCM.
Specific genotypes affect the resolution or the
left ventricular remodelling in post-myocarditis
dilated cardiomyopathy
The presence of potentially harmful polymorphism of the
genes responsible for genetically determined cardiomyop-
athies appears to be also correlated with acute myocarditis
and the development of post-myocarditis DCM.17 Amyocar-
dial viral infection can trigger the progression of hypertro-
phic cardiomyopathy or DCM secondary to Duchenne
Figure 1 Schematic representation of the processes involved in the progression form myocarditis to dilated cardiomyopathy or its resolution.
Table 3 Main cardiotrophic viruses and prevalence of the vi-
ral genome persistence in patients with biopsy-proven
myocarditis
Cardiotrophic virus Percentage
Coxsackievirus B3 (CVB3) 14–32.6
Parvovirus B19 (PB19) <1–36.6
Human herpesvirus 6 (HHV6) 10.5
Adenovirus 8.1–23
Multiple Infections (60% of the
cases ¼ PB19 þ HHV6)
12.2
Rare cases
Citomegalovirus <3
Epstein–Barr virus <1
Herpes simplex virus <1
Inﬂuenza virus <2
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muscular dystrophy,22 likely through an interaction be-
tween viral proteases and cytoskeleton proteins.
Furthermore the association between arrhythmogenic car-
diomyopathy and myocarditis is well known. Akin to the
animal models of myocarditis,23 mutations affecting
the genes codifying for cytoskeleton proteins increase the
myocardial susceptibility to viral infection as well as the
development of DCM. Some mutation affecting cytoskele-
ton proteins, such as dystrophin, predispose these proteins
to cleavage by viral proteases,magnifying the vicious circle
leading to unfavourable evolutions.24 Several potentially
harmful genetic variants, such as desmoplakin (DSP), proki-
neticin 2 (PK2), and cardiac troponin (TNNI3), are associ-
ated with progression of post-myocarditis DCM, whether
other genes associated with cardiomyopathies, SCN5A (so-
dium channels) and BAG3 (Bcl-2–associated athanogene 3),
seems to portend a less severe progression.17
In summary, in humans as well, structural genetic modifi-
cations would favour the persistence and progression of
myocarditis, whether mutations affecting genes codifying
for non-structural proteins portend to a more favourable
progression.17,18 It is still not clear if the viral infection is
directly responsible for the development of DCM, or, in-
stead, it represents a trigger for the manifestation of a ge-
netically determined DCM (Figure 1). Accordingly the
complete understanding of the mechanisms leading to
post-myocarditis DCM, and an improved stratification of
the patients, necessitates a strict interaction between clin-
ical and basic research. The new genetic sequencing tech-
niques as well the opportunity to test the impact of the
inflammatory insult both in vivo and in vitro will help iden-
tifying genes involved in this process, leading to ever more
individualized treatments.
Conclusions and future perspectives
The key question still remains: is myocarditis the offending
cause which uncover the myocardial genetic anomalies, or
the genetic alterations render the myocardium prone to
myocarditis and its evolution towards DCM?
The answer to this question will necessitate genetic in-
vestigation on wide panels of genes of patients with myo-
carditis both in the regression and in the progressive phase.
The identification of genetic mutation or specific genes re-
sponsible for the complex interaction between bio-
molecular mechanism and offending agents will represent
the challenge of the future research aiming at refining pre-
cisionmedicinewhich goal is to individualize the treatment
of patients with myocarditis and preventing its progression
towards chronic cardiomyopathy.
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